Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Diagnostic Markers Top Celera's Agenda Following Sequencing Coup

This article was originally published in The Gray Sheet

Executive Summary

Colon, pancreatic and breast cancers are initial disease areas for which Celera Genomics plans to develop diagnostic markers. In support of the effort, Celera will expand its high-throughput screening capability with the construction of a proteomics facility at the firm's Rockville, Maryland headquarters this spring.

You may also be interested in...



Exact Sciences' $56 Mil. IPO Readies Firm For Colorectal Cancer Screen Trial

Exact Sciences will use about $19 mil. of its $56 mil. initial public offering to fund a 5,300-patient, 40-center clinical trial evaluating genomics-based diagnostics to screen for colorectal cancer.

PE Biosystems Eyeing Spin-out Of Expanded Molecular Diagnostic Business

PE Corp. is looking to leverage the capabilities of its two component business units, PE Biosystems and Celera Genomics, to increase the company's presence in the molecular diagnostics field, most likely through a spin-out of the new operation.

Interview: Novartis's Big Hopes For Beovu

After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
UsernamePublicRestriction

Register

MT014491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel